Comparison of the Atmo Motility Gas Capsule System to the Reference Standard
Completed · Not applicable · NCT05718505
Conditions: Gastroparesis, Slow Transit Constipation, IBS
At a glance
- Research payments reported, 2025
- $2,172
- U.S. investigators named
- 1
- Sites paid
- 0
- Planned or actual enrollment
- 209
About the trial
- Sponsor
- Atmo Biosciences Pty Ltd
- Tested
- Atmo Motility Gas Capsule System (device), SmartPill Monitoring System (device)
- Dates
- Started 2023-06-05; completion 2024-05-17
- Results posted
- Not yet
The study objective is to demonstrate the equivalence of the Atmo Motility Gas Capsule System with the predicate SmartPill in measuring gastric emptying time and colonic transit time through examination of device agreement.
From ClinicalTrials.gov, last updated 2026-10-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Atmo Biosciences Inc reported $2,172 in research payments for this study in 2025 (8 payments).
Products named: Atmo Biosciences
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $2,172
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.